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Abstract
This account surveys the current progress on the application of intra- and intermolecular enyne metathesis as main key steps in the
synthesis of challenging structural motifs and stereochemistries found in bioactive compounds. Special emphasis is placed on ruthe-
nium catalysts as promoters of enyne metathesis to build the desired 1,3-dienic units. The advantageous association of this ap-
proach with name reactions like Grignard, Wittig, Diels–Alder, Suzuki–Miyaura, Heck cross-coupling, etc. is illustrated. Examples
unveil the generality of such tandem reactions in providing not only the intricate structures of known, in vivo effective substances
but also for designing chemically modified analogs as valid alternatives for further therapeutic agents.
Introduction
Alkene and alkyne metathesis [1-4], constituting highly versa-
tile and powerful catalytic processes for constructing complex
organic molecules [5-12], have found broad application in the
fields of pharmaceutical synthesis [13-15], materials science
[16-20], or in advanced techniques and technologies [21-30].
Thus, numerous multistep total syntheses of organic com-
pounds, including bioactive molecules [31-35] and natural prod-
ucts [36,37], have been performed in a highly chemo- and
stereoselective manner through metathesis routes [38-43]. In
ingeniously elaborated procedures, olefin metathesis has been
frequently employed as such or associated with name reactions
like Grignard, Wittig, Diels–Alder, Suzuki–Miyaura, Heck, etc.,
resulting in the assembly of diverse intricate building blocks of
the targeted structures [44]. Among the various embodiments of
olefin metathesis, the highly chemoselective enyne metathesis
reaction [45-49] has led to some of the most striking advances
in the development of modern, efficient synthetic protocols
[50,51]. Thus, the present account focuses on the impressive
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Scheme 1: Intramolecular (A) and intermolecular (B) enyne metathesis reactions.
Scheme 2: Ene–yne and yne–ene mechanisms for intramolecular enyne metathesis reactions.
potential of enyne metathesis in providing sustainable access to
bioactive organic compounds, when used in conjunction with a
number of name reactions.
Enyne metathesis is a fundamental chemical transformation in-
volving an alkene and an alkyne to produce a dienic structure
through unsaturated bond reorganization [45,46]. This process
may follow an intra- or intermolecular course (Scheme 1, A or
B). The reaction is promoted by an array of metathesis catalytic
systems, particularly derived from Mo, W, or Ru carbenes or it
is induced by specific conventional transition-metal salts.
It should be pointed out that enyne metatheses are atom eco-
nomical processes driven by the enthalpic stability of the conju-
gated diene products. Depending on the steric requirements of
the transition metal carbene and of the starting enyne, the intra-
molecular reaction can proceed either via ene–yne or yne–ene
pathways to yield the respective dienic compounds (Scheme 2)
[52].
The reaction course is essential for directing the process
towards the desired exo or endo isomer, in compliance with the
required stereochemistry of the final product. For the intermo-
lecular enyne metathesis reaction, the double bond of the alkene
is coordinated to the metallacarbene and cleaved (Scheme 3 (a))
and the formed alkylidene species is inserted into the alkyne
unit through a metallacyclobutene intermediate. This metallacy-
clobutene, through the rearrangement to a vinyl metal-alkyl-
idene (Scheme 3 (b)) and subsequent metathesis with the alkene
(Scheme 3 (c)) leads to the expected 1,3-diene (Scheme 3
(d–f)).
A particular advantage of the enyne metathesis is that the
stereoselectivity can be readily controlled by the intramolecular
vs the intermolecular process. Among the vast array of bioac-
tive organic molecules already synthesized through enyne me-
tathesis as a key step, we herein survey representative exam-
ples where this reaction is effectively associated with tradi-




Due to its biological relevance, artemisinin, a tricyclic com-
pound bearing a peroxide bridge, has been subject of extensive
scientific investigations during the last decade [53-63]. In this
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 3: Metallacarbene mechanism in intermolecular enyne metathesis.
context, Seeberger and co-workers successfully developed an
ingenious continuous-flow process for the hemisynthesis of
pure artemisinin from dihydroartemisinic acid (DHAA) [64,65].
Also, high efficient and recyclable catalytic systems based on
metal-organic frameworks (MOFs) have also been reported for
the tandem hemisynthesis of artemisinin [66]. In a remarkable
work, this antimalarial drug was obtained by a new route in-
volving enyne metathesis as the key step, adding this protocol
to the existing synthetic or hemisynthetic procedures. Along
this line, Oguri et al. elaborated an excellent strategy for assem-
bling the tricyclic diene scaffold of artemisinin and its analogs
that combines classical transformations with tandem dienyne
ring-closing metathesis (RCM) [67,68]. Starting from
3-cyanocyclohex-2-enone, the authors obtained a versatile inter-
mediate able to provide the appropriate dienyne precursors
(A–C, Scheme 4) by multicomponent Grignard addition-alkyl-
ations. Through divergent cyclizations involving a chemoselec-
tive enyne metathesis catalyzed by Grubbs 2nd generation
Ru-carbene, these intermediates then led to the tricyclic
sesquiterpenoid-like scaffolds I–VIII (Scheme 4), as suitable
precursors for the synthesis of artemisinin and its analogs
(1a–c). After selecting the optimal tricyclic intermediate, the
installation of the bridged peroxide groups in the corresponding
artemisinin analog was eventually achieved by applying further
oxidation.
In a similar way to the above Oguri protocol, Li et al. prepared
nanolobatolide (2), a potent neuroprotective agent, by success-
fully applying a tandem ring-closing metathesis of dienynes and
subsequent Eu(fod)3-catalyzed intermolecular Diels–Alder
cycloaddition and epoxidation reactions (Scheme 5) [69]. In this
stereoselective synthesis, the last biomimetic step was critical to
obtain the proper enantiomer of the tetracyclic core of nanolo-
batolide.
Amphidinolide macrolides
Amphidinolides constitute a broad family of natural macrolides
that act as powerful cytotoxic agents against various cancer cell
lines. Due to the stereochemical intricacy and high cytotoxicity,
these compounds have attracted a great deal of attention from
synthetic chemists. The application of an intermolecular enyne
metathesis in tandem with a diene cross-metathesis as the
crucial steps were reported by Lee in the total synthesis of
(−)-amphidinolide E (3) (Scheme 6) [70]. It is noteworthy that
the second-generation Grubbs catalyst was quite active and
stereoselective for both the enyne and cross-metathesis steps,
thereby affording the triene intermediate in a substantial yield.
Additional transformations using conventional methods effi-
ciently provided (−)-amphidinolide E (3).
Amphidinolide K, another important bioactive macrolide
endowed with specific cytotoxic activity against L1210 and KB
cancer cells, was also obtained by Lee who carried out an inter-
molecular enyne metathesis between an alkynyl boronate and an
olefinic substrate in the presence of the Grubbs 2nd generation
catalyst [71]. The reaction was highly stereoselective and
favored the formation of the desired E-isomer (E/Z = 7.5:1).
The functionalization of the dienic compound through a
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 4: The Oguri strategy for accessing artemisinin analogs 1a–c through enyne metathesis.
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Scheme 5: Access to the tetracyclic core of nanolobatolide (2) via tandem enyne metathesis followed by an Eu(fod)3-catalyzed intermolecular
Diels–Alder cycloaddition, an epoxidation, and a biomimetic epoxide opening.
Scheme 6: Synthesis of (−)-amphidinolide E (3) using an intermolecular enyne metathesis as the key step.
Suzuki–Miyaura coupling and Julia–Kocienski olefination, fol-
lowed by a Yamaguchi lactonization, and an asymmetric epoxi-
dation in the presence of (+)-diethyl tartrate, conveniently pro-
duced (−)-amphidinolide K (4, Scheme 7).
In a remarkable work, Trost et al. [72] accomplished the
convergent synthesis of des-epoxy-amphidinolide N (5) in 33
total steps (22 longest linear). To this end, after three genera-
tions of synthetic attempts, they succeeded joining the northern
and southern fragments of des-epoxy-amphidinolide N, both
endowed with a considerable level of structural complexity, by
essentially using a Ru-catalyzed alkene–alkyne (Ru-AA) cou-
pling reaction and a macrolactonization step (Scheme 8).
In this carefully designed total synthesis, after applying a
Marshall coupling reaction aimed at installing a propargyl
group into the initial acetylene component, an enyne metathesis
between the formed propargylic derivative and an appropriate
allylic alcohol promoted by the Grubbs second-generation cata-
lyst, finally produced in high yield (85%) the intermediate diene
6, as an essential building block for the southern fragment
(Scheme 9).
Several other asymmetric transition-metal-catalyzed transfor-
mations were needed to achieve the total synthesis of des-
epoxy-amphidinolide N, including a palladium asymmetric
allylic alkylation (Pd-AAA), a Mukaiyama aldol reaction (with
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 7: Synthesis of amphidinolide K (4) by an enyne metathesis route.
Scheme 8: Trost synthesis of des-epoxy-amphidinolide N (5) [72].
Scheme 9: Enyne metathesis between the propargylic derivative and the allylic alcohol in the synthesis of the southern fragment of des-epoxy-
amphidinolide N.
Sn), and a Krische allylation (with Ir) [72]. As special feature of
this procedure, an Evans aldol reaction generated the syn aldol
adduct, having the steric configuration imposed in des-epoxy-
amphidinolide N. Also, in the last step of their work, Trost et al.
managed to install the C14-OH via a finely tuned Rubottom oxi-
dation that finalized the total synthesis of des-epoxy-amphidi-
nolide N. Strikingly, an intramolecular Ru-catalyzed alkene-
alkyne (Ru-AA) coupling and a late-stage epoxidation were
readily accomplished, while the installation of the α,α′-di-
hydroxy ketone through a dihydroxylation proved difficult.
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 10: Synthetic route to amphidinolide N (6a).
Noteworthy, the structural elucidation of the THP ring of des-
epoxy-amphidinolide N evidenced the hydrogen-bonding
network of amphidinolide N (6a, Scheme 10).
Furthermore, a rigorous evaluation of the 13C NMR chemical
shift differences suggested that amphidinolide N and its analog,
carbenolide I, are identical chemical compounds [72].
In the course of their comprehensive studies on the total synthe-
sis of amphidinolides [73-75], Fürstner et al. applied both ring-
closing alkyne metathesis and intramolecular enyne metathesis
with ethylene in a sequential mode for the synthesis of amphidi-
nolide V (7) [75]. As a special merit of this original protocol,
the macrocyclization of the stereoisomeric diyne precursors was
performed first by a ring-closing alkyne metathesis in the pres-
ence of Schrock’s molybdenum catalyst. Next, the diene units
were installed by intermolecular enyne metathesis of the
preformed cyclic alkyne with ethylene using Grubbs second-
generation ruthenium catalyst (Scheme 11). This innovative
methodology allowed the installation of the vicinal exo‐methy-
lene branches characteristic for the cytotoxic marine natural
product amphidinolide V as well as the determination of its
absolute configuration. It further enabled the synthesis of a set
of diastereomers and analogs of amphidinolide V, whose bio-
logical activities were thoroughly evaluated. It is important to
note, that the analogs of amphidinolide V designed by Fürstner
gave the first insights into the structure–activity relationships
for this family of compounds and revealed that the steric struc-
ture of the macrolactone is a highly critical parameter for their
activity, while certain alterations of the side chain do not affect
the cytotoxicity to a notable extent.
Anthramycin
In an interesting approach to the protected precursor 8 of
(+)-anthramycin (8a), a compound with strong antitumor
activity having a pyrrolobenzodiazepine structure, Mori et al.
[76] successfully combined an enyne metathesis and an alkene
cross-metathesis in an efficient sequential manner under the
action of both the Grubbs first-generation and Hoveyda–Grubbs
second-generation catalysts. According to this procedure,
initially an enyne precursor was synthesized starting from
ʟ-methionine. The subsequent enyne ring-closing metathesis in
the presence of the Grubbs first-generation catalyst (5 mol %)
afforded a pyrrolidine derivative in 76% yield (Scheme 12).
This pyrrolidine was converted into a pyrrolo-1,4-benzodi-
azepinone bearing a vinyl side group, which underwent a cross-
metathesis with ethyl acrylate in the presence of the
Hoveyda–Grubbs second-generation-type catalyst (10 mol %)
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 11: Synthesis of the stereoisomeric precursors of amphidinolide V (7a and 7b) through alkyne ring-closing metathesis and enyne metathesis
as the key steps.
Scheme 12: Synthesis of the anthramycin precursor 8 from ʟ-methionine by a tandem enyne metathesis–cross metathesis reaction.
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Scheme 13: Synthesis of (−)‐clavukerin A (9) and (−)‐isoclavukerin A (10) by an enyne metathesis route starting from (S)- and (R)-citronellal.
Scheme 14: Synthesis of (−)-isoguaiene (11) through an enyne metathesis as the key step.
leading to the corresponding vinyl ester 8 in 63% yield, as a
convenient precursor to (+)-anthramycin. The latter was ob-
tained via an isomerization of the double bond in the pyrrol-
idine ring catalyzed by RhCl3·H2O, followed by debenzylation,
amidation, and aminal generation using the Stille protocol [77].
(–)‐Clavukerin A and related sesquiterpenes
Applying original organocatalytic/metal-catalyzed tactics, Metz
et al. [78] reported a tandem dienyne RCM for the synthesis of
the marine sesquiterpenoid (−)‐clavukerin A (9) and its stereo-
isomer (−)‐isoclavukerin A (10, Scheme 13). The sterically
related analogs (+)-clavularin A and clavularin B have also
been produced by this protocol. It is noteworthy, that the
authors succeeded in preparing the two enantiopure dienyne
precursors in three steps, from (S)- and (R)-citronellal, through
a diastereoselective Michael addition, chemoselective
dibromoolefination, and a one-pot Wittig olefination/alkyne-
bond formation. The enantiopure dienynes were then converted
into the enantiomeric hydroazulenes in 53% and 55% yield,
respectively, by domino metathesis reactions using the
Hoveyda–Grubbs catalyst (4 mol %). In the final step,
(−)‐clavukerin A was effectively converted into (+)-clavularin
A and the latter epimerized to (−)-clavularin B.
Recently, (–)-isoguaiene (11), a member of the guaiane
sesquiterpenes and structurally related to the trinorsesquiter-
pene (−)‐clavukerin A, was also communicated by Metz et al.
[79] using an enyne metathesis reaction as a key step. The
authors performed a relay metathesis of the trienyne or
diene–diyne precursors in the presence of the second-genera-
tion Grubbs catalyst (Scheme 14). The enantiopure trienyne or
diene–diyne metathesis precursors were readily obtained from
(S)-citronellal by a highly diastereoselective organocatalytic
Michael addition.
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 15: Synthesis of erogorgiaene (12) by a tandem enyne metathesis/cross metathesis sequence using the second-generation
Hoveyda–Grubbs catalyst.
Erogorgiaene
An exceptionally stereoselective synthesis of erogorgiaene (12)
(95% E-selectivity) was reported by Hoveyda et al. [80]. They
combined an enyne ring-closing metathesis and an alkene cross-
metathesis reaction in a sequential mode, using the appropriate
enantiopure enynes and the Hoveyda–Grubbs catalyst in
both transformations (Scheme 15). High yields and excellent
chemoselectivities toward the diene products were attained in
both metathesis steps applying the second-generation
Hoveyda–Grubbs Ru catalyst, while, unexpectedly, the second-
generation Grubbs ruthenium catalyst was less active and gave
rise to some side-products.
(−)-Galanthamine
An important alkaloid active in the treatment of mild to moder-
ate Alzheimer's disease and other memory impairments, namely
(−)-galanthamine (13), has attracted great interest for its struc-
tural complexity and specific bioactivity. The total synthesis of
compound 13, described by Brown et al. [81], involved an
enyne ring-closing metathesis and a Heck cross-coupling as the
key reactions for constructing the five-membered oxacyclic
ring. As stated in this protocol, a functionalized enyne precur-
sor was prepared in several steps with high enantioselectivity
(92% ee), starting from isovanillin. This precursor underwent a
ring-closing metathesis in the presence of the Grubbs first-gen-
eration Ru catalyst (3 mol %) to give the corresponding 1,3-
diene intermediate in 85% yield (Scheme 16). The subsequent
hydroboration and oxidation to homoallylic alcohol, followed
by a palladium-catalyzed Heck cross-coupling, an allylic oxida-
tion with SeO2, mesylation, and deprotection, afforded
(−)-galanthamine (13) as the final product.
Kempene diterpenes
The first enantioselective synthesis of kempene diterpenes
14a–c, natural compounds exhibiting a significant antibiotic ac-
tivity against B. subtilis, relying on the domino enyne metathe-
sis of the adequate dienyne precursors as a key step, was
disclosed by Metz et. al. [82]. The starting dienynes were ob-
tained in a high enantiomeric purity starting form 2,6-dimethyl-
1,4-benzoquinone and isoprene via an asymmetric Diels–Alder
reaction. The domino metathesis reactions induced by the
Grubbs second-generation catalyst proceeded in good yield
(92%) thereby affording a protected tetracyclic kempane deriva-
tive. The latter was further converted into (+)-kempene-2 (14a)
in 91% yield by deprotection and acetylation (Scheme 17). A
reduction of the intermediate ketone with lithium aluminum
hydride followed by an acetylation finally led to (+)-kempene-1
(14b) and (+)-3-epi-kempene-2 (14c). Importantly, the tandem
metathesis of the dienyne precursor could also be performed in
good yield (82%) with the Grubbs first-generation Ru catalyst
(10 mol %).
(+)-Lycoflexine alkaloid
In 2010, Ramharter and Mulzer [83] prepared an intricate
tricyclic intermediate useful for the total synthesis of the alka-
loid (+)-lycoflexine (15). In this strategy, first a protected
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 16: Synthesis of (−)-galanthamine (13) from isovanilin by an enyne metathesis.
Scheme 17: Application of enyne metathesis for the synthesis of kempene diterpenes 14a–c.
dienyne precursor was prepared that, by an enyne tandem ring-
closing metathesis induced by the Grubbs second-generation Ru
catalyst, produced a tricyclic diene in 52% yield. Next, a selec-
tive hydrogenation of the cis-disubstituted double bond in the
latter was performed under a high pressure of hydrogen, leading
to the saturated tricyclic scaffold that was used as a key inter-
mediate in the total synthesis of lycoflexine (15, Scheme 18).
Manzamine alkaloids
A highly interesting application of a metathesis reaction for
accessing bioactive organic molecules is found in the complex
synthesis of manzamine alkaloids. These efficient antitumor
agents, originally isolated from several genera of marine
sponges, contain a pentacyclic core with a pendant β-carboline
moiety. Their total synthesis implies an elaborate assembly of
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 18: Synthesis of the alkaloid (+)-lycoflexine (15) through enyne metathesis.
the subunits leading to the pentacyclic scaffold. Previously, the
AB ring system of manzamines was constructed mainly using
Diels–Alder reactions [84,85]. Thus, Fukuyama et al. [85] de-
scribed an elegant approach for the synthesis of (+)-manzamine
A in a totally stereoselective manner relying on a Diels–Alder
cycloaddition, an intramolecular Mitsunobu reaction, a [3,3]-
sigmatropic rearrangement, and a ring-closing metathesis. As an
alternative to this approach, Clark et al. [86] efficiently per-
formed a sequential Ru-catalyzed enyne metathesis in combina-
tion with a hydroboration, and an aminohydroxylation. For this
purpose, they first prepared the properly functionalized
(–)-quinines from quinoline derivatives in six steps. These
chiral intermediates were then submitted to an enyne metathe-
sis reaction with the Grubbs first-generation Ru catalyst
(10 mol %), under an ethylene atmosphere, to generate the cor-
responding bicyclic dienic scaffolds. The subsequent hydro-
boration and aminohydroxylation carried out on these bicyclic
dienes provided the AB subunit as a key intermediate compo-
nent of manzamines A (16a) and E (16b, Scheme 19). Eventu-
ally, several highly elaborated transformations of the AB
subunit, including Diels–Alder cycloaddition and advanced
functionalization reactions, gave access to manzamine A and E.
Rhodexin A
Jung et al. [87-89] succeeded in the stereoselective synthesis of
rhodexin A (17), a steroid with potent cardiotonic properties
and with activity against human leukemia K562 cells [87,88]. In
this innovative work, the authors effectively combined an enyne
metathesis promoted by the Grubbs first-generation catalyst and
an alkene cross-metathesis induced by the Grubbs second-gen-
eration catalyst with reverse electron-demand Diels–Alder
cycloadditions (Scheme 20). In contrast to the majority of
steroids that are trans-fused, rhodexin A comprises cis-fused
AB and CD rings. By carefully selecting the reaction condi-
tions, they managed to impose this stereochemistry in all syn-
thetic steps participating in the construction of the tetracyclic
ring system of rhodexin A.
Securinega alkaloids
The total synthesis of the Securinega alkaloids, (−)-flueggine A
(18) and (+)-virosaine B (19), which are potent anticancer
agents, was proposed by Wei et al. [90] via a relay ring-closing
metathesis (RRCM) associated with a 1,3-dipolar cycloaddition.
The enyne precursors bearing a dienic relay unit, were prepared
from Weinreb amide by an asymmetric pathway, were reacted
with either the Grubbs second-generation catalyst, the
Hoveyda–Grubbs second-generation catalyst, or the Zhan cata-
lyst, the latter giving under the optimized conditions the highest
yield of the expected dihydrobenzofuranones. Ultimately,
(−)-flueggine A and (+)-virosaine B were obtained by 1,3-
dipolar addition reactions (Scheme 21).
Virgidivarine and virgiboidine
In 2013, Blechert et al. [91] devised an original methodology
applying enyne metathesis as the key step for the total
synthesis of virgidivarine (3-carboxy-N-(4'-butenyl)-5-(2'-
piperidyl)piperidine) (20) and virgiboidine (3-but-3-en-1-
yl)decahydro-6H-1,5-methanopyrido[1,2-a][1,5]diazocin-6-
one) (21), two important pharmacologically active compounds
containing dipiperidine and piperidino-quinolizidine units in
their structure. Starting from the monoacetate of cyclopentene-
1,4-diol that was obtained by the enzymatic desymmetrization
of the corresponding diacetate, an enyne metathesis precursor
was accessed by a Mitsunobu-type coupling reaction with
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 19: Synthesis of the AB subunits of manzamine A (16a) and E (16b) by enyne metathesis.
Scheme 20: Jung's synthesis of rhodexin A (17) by enyne metathesis/cross metathesis reactions.
propargylic amide. The ring-rearrangement metathesis (RRM)
of this enyne precursor was carried out using the second-gener-
ation Hoveyda–Grubbs catalyst (5 mol %, 83% yield), under an
ethylene atmosphere. The subsequent regioselective NaIO4-
mediated oxidative cleavage of the pendant double bond, fol-
lowed by the installation of the unsaturated N-butenyl group,
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 21: Total synthesis of (−)-flueggine A (18) and (+)-virosaine B (19) from Weinreb amide by enyne metathesis as the key step.
Scheme 22: Access to virgidivarine (20) and virgiboidine (21) by an enyne metathesis route.
oxidation, and deprotection provided the final products 20 and
21 (Scheme 22).
(−)-Zenkequinone
Also in 2013, Vangan and Kaliappan [92] disclosed an attrac-
tive protocol for the synthesis of (−)-zenkequinone B (22), a po-
tent bioactive compound, by ring-closing enyne metathesis in
the presence of the Grubbs first-generation Ru catalyst. Accord-
ing to this method, an enyne precursor was first converted into
an exocyclic 1,3-diene in 92% yield. A Diels–Alder reaction
with naphthoquinone and a deprotection step then led to the
final compound (−)-zenkequinone B in a stereoselective manner
(Scheme 23).
C-Aryl glycosides
Another interesting report from Kaliappan et al. [93] described
a highly efficient synthesis of C-aryl glycosides, which are
naturally occurring compounds of biological relevance. Starting
Beilstein J. Org. Chem. 2020, 16, 738–755.
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Scheme 23: Enyne metathesis approach to (−)-zenkequinone B (22).
Scheme 24: Access to C-aryl glycoside 23 by an intermolecular enyne metathesis/Diels–Alder cycloaddition.
Scheme 25: Synthesis of spiro-C-aryl glycoside 24 by a tandem intramolecular enyne metathesis/Diels–Alder reaction/aromatization.
from a glycoside precursor, the intermolecular enyne metathe-
sis with ethylene gas in the presence of the second-generation
Grubbs catalyst allowed the installation of the1,3-diene units at
the anomeric center of the future C-aryl glycoside (23) in high
yields (94–98%, Scheme 24). Alternatively, an intramolecular
enyne metathesis promoted by the first-generation Grubbs cata-
lyst produced the spiro-C-aryl glycoside 24 from sugar enyne
precursors (Scheme 25). Subsequent Diels–Alder cycloaddition
reactions with dienophiles and further aromatization reactions
paved the way for a convenient access to structurally diverse
Beilstein J. Org. Chem. 2020, 16, 738–755.
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polycyclic compounds. For instance, installing the C-aryl and
spiro-C-aryl glycosides in the same moiety was successfully
achieved. An application of this concept to obtain the core
structure of gilvocarcin, a natural C-aryl glycoside, was also re-
ported. Moreover, the authors attempted a tandem enyne me-
tathesis/Diels–Alder/aromatization to directly prepare the C-aryl
glycosides in a one-pot protocol.
(−)-Exiguolide
The first stereoselective synthesis of the (−)-exiguolide enantio-
mer (25) was reported by Roulland et al. [94]. The method is a
mechanistically distinct alternative to the enyne metathesis
since it involves a Trost’s Ru-catalyzed enyne cross-coupling
reaction associated with a Yamaguchi lactonization, a Grubbs
Ru-catalyzed cross-metathesis, and a one-pot, two-step stereo-
selective conjugated allylic alcohol substitution (Scheme 26). It
should be emphasized that in this convergent synthesis of
(−)-exiguolide, the authors achieved a rigorous stereocontrol of
both the exocyclic and endocyclic double bond geometries, as
well as the stereoselective formation of the tetrahydrofuran
rings.
Scheme 26: Pathways to (−)-exiguolide (25) by Trost’s Ru-catalyzed
enyne cross-coupling and cross-metathesis [94].
Conclusion
This review highlighted the most recent efforts regarding the
development of enyne metathesis-based syntheses of complex
bioactive, natural and nonnatural organic molecules. Both,
intra- and intermolecular enyne metatheses have been valorized
to efficiently produce key 1,3-dienic frameworks, further sub-
jected to sequential functionalization. The main focus was
placed on strategies combining enyne metathesis with tradi-
tional chemical transformations such as Diels–Alder cycloaddi-
tion, Suzuki–Miyaura or Heck cross-couplings, aromatization,
epoxidation, hydroxylation, etc. This point of view has allowed
to master a concise access to the target products which require
exceptional chemical and stereochemical complexity. The
excellence of the Grubbs- and Schrock-type metathesis cata-
lysts as selective and proficient promoters of enyne metathesis
was emphasized. The review also shed light on the continuous
improvement of protocols relying on this reaction, potentially
leading to tailorable properties of earmarked therapeutic agents.
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